Integra LifeSciences Holdings (IART)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | -0.67% | 2.49% | 11.34% | 10.37% | 65.53% |
| Operating profit margin | 1.77% | 7.50% | 15.86% | 12.86% | 11.66% |
| Pretax margin | -1.13% | 5.45% | 14.20% | 14.00% | 7.20% |
| Net profit margin | -0.43% | 4.56% | 11.98% | 11.02% | 10.31% |
Integra LifeSciences Holdings' profitability ratios have shown significant fluctuations over the years. The gross profit margin decreased from 65.53% in 2020 to -0.67% in 2024, indicating a decline in the company's ability to generate profit after accounting for the cost of goods sold.
Similarly, the operating profit margin fluctuated, starting at 11.66% in 2020, peaking at 15.86% in 2022, and declining to 1.77% in 2024. This suggests that operational efficiency and profitability have varied over the period analyzed.
The pretax margin also displayed volatility, with a downward trend from 7.20% in 2020 to -1.13% in 2024. This indicates a decreasing ability to generate profit before accounting for taxes.
Overall, the net profit margin experienced fluctuations, ranging from 10.31% in 2020 to -0.43% in 2024, reflecting the company's varying levels of profitability after all expenses are accounted for.
In summary, Integra LifeSciences Holdings' profitability ratios have fluctuated significantly over the years, indicating challenges in maintaining consistent profitability and operational efficiency. It is essential for the company to focus on improving its cost management and revenue generation to enhance its overall profitability.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 0.70% | 2.95% | 6.14% | 5.21% | 4.19% |
| Return on assets (ROA) | -0.17% | 1.79% | 4.64% | 4.47% | 3.70% |
| Return on total capital | 1.08% | 4.44% | 8.49% | 8.62% | 5.65% |
| Return on equity (ROE) | -0.45% | 4.27% | 10.01% | 10.04% | 8.84% |
Integra LifeSciences Holdings has displayed variable profitability trends over the years based on the provided financial ratios. The Operating Return on Assets (Operating ROA) has shown an improving trend from 4.19% in 2020 to 6.14% in 2022, indicating that the company has been able to generate more operating income relative to its assets over this period. However, there was a notable decline in 2023 to 2.95% followed by a substantial drop to 0.70% in 2024, which suggests a possible decline in operational efficiency.
The Return on Assets (ROA) also reflects a similar pattern, starting at 3.70% in 2020 and reaching a peak of 4.64% in 2022 before dropping significantly into negative territory at -0.17% in 2024. This suggests that the company may be struggling to generate profits relative to its total assets in the most recent year.
The Return on Total Capital has seen fluctuations as well, with an increase from 5.65% in 2020 to 8.62% in 2021 and 8.49% in 2022. However, this ratio experienced a decline to 1.08% in 2024, indicating possible challenges in generating returns for both debt and equity holders.
Furthermore, the Return on Equity (ROE) exhibited a similar trend to the ROA and ROA ratios, with an increase from 8.84% in 2020 to 10.04% in 2021 and 10.01% in 2022. Subsequently, the ratio dropped to -0.45% in 2024, implying that the company may not be effectively utilizing equity investments to generate profits for shareholders.
In sum, the profitability ratios of Integra LifeSciences Holdings show a mixed performance, with improvements in certain years followed by declines in others, indicating potential challenges in maintaining consistent profitability and effectively utilizing assets and capital to generate returns for investors.